Combination of encorafenib, binimetinib and cetuximab demonstrated an 8 month median PFS
Array BioPharma and Pierre Fabre announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF-mutant CRC. January 20, 2018